Chronic Granulomatous Disease (CGD) is a rare, inherited immunodeficiency caused by mutations in one or more components of the NADPH oxidase complex. This defect compromises the ability of phagocytes ...

BOSTON--(BUSINESS WIRE)--Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo treatments capable of precisely and durably engineering the hematopoietic system ...

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, ...

A collaborative effort between investigators at the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding ...

Genetic medicine outfit Ensoma is halving its workforce, with most of the impacted roles related to platform research ...

Ensoma Inc.’s lead program, EN-374, has been granted orphan drug and rare pediatric disease designations by the FDA for the treatment of X-linked chronic granulomatous disease. Ensoma anticipates ...

CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic ...

ZURICH, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Somagenetix AG, a pioneering biotech company dedicated to revolutionizing gene therapy for phagocyte disorders, announced today the initial closing of its ...

A collaborative effort between investigators at the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding ...

The CRISPR molecular scissors have the potential to revolutionize the treatment of genetic diseases. This is because they can be used to correct specific defective sections of the genome.